{"id":"pioglitazone-rosiglitazone","safety":{"commonSideEffects":[{"rate":"5–10","effect":"Weight gain"},{"rate":"5–15","effect":"Fluid retention / edema"},{"rate":"null","effect":"Hypoglycemia (when combined with other agents)"},{"rate":"null","effect":"Heart failure exacerbation"},{"rate":"null","effect":"Bone fractures (increased risk)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs bind to PPAR-γ, a nuclear receptor involved in glucose and lipid metabolism, enhancing insulin sensitivity in muscle, adipose tissue, and liver. By reducing insulin resistance, they lower fasting and postprandial glucose levels without directly stimulating insulin secretion. This mechanism makes them effective for glycemic control in type 2 diabetes, though they carry metabolic side effects including weight gain and fluid retention.","oneSentence":"Pioglitazone and rosiglitazone are thiazolidinediones that activate peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:25.807Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT00297063","phase":"PHASE3","title":"BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-11","conditions":"Diabetes Mellitus, Type 2","enrollment":350},{"nctId":"NCT00964106","phase":"PHASE1","title":"Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-26","conditions":"Drug Interactions","enrollment":87},{"nctId":"NCT01055223","phase":"","title":"Fracture Risk With Thiazolidinediones","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Fractures, Bone, Type II Diabetes","enrollment":98483},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00879970","phase":"PHASE4","title":"Thiazolidinedione Intervention With Vitamin D Evaluation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1332},{"nctId":"NCT00481663","phase":"PHASE2","title":"A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08-19","conditions":"Type II Diabetes Mellitus","enrollment":555},{"nctId":"NCT00402909","phase":"PHASE4","title":"Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT00742326","phase":"PHASE4","title":"Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-08","conditions":"HIV, Hepatitis C, Liver Disease","enrollment":13},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00396227","phase":"PHASE3","title":"Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":2665},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT00437970","phase":"PHASE4","title":"Medication in Early Diabetes (MED) Study","status":"WITHDRAWN","sponsor":"Menzies School of Health Research","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT00232362","phase":"PHASE1","title":"Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Texas Tech University Health Sciences Center","startDate":"2007-06","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00295633","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Diabetes Mellitus, Type 2","enrollment":565},{"nctId":"NCT01174056","phase":"EARLY_PHASE1","title":"Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-07","conditions":"Lung Inflammation","enrollment":39},{"nctId":"NCT00680745","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":597},{"nctId":"NCT00953498","phase":"PHASE4","title":"Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2007-10","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT00331487","phase":"PHASE3","title":"Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-09","conditions":"Diabetes Mellitus","enrollment":719},{"nctId":"NCT00672919","phase":"PHASE4","title":"Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-11","conditions":"Diabetes Mellitus","enrollment":305},{"nctId":"NCT00314561","phase":"PHASE4","title":"The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2006-05","conditions":"Metabolic Syndrome","enrollment":40},{"nctId":"NCT01088594","phase":"PHASE1","title":"A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus","enrollment":12},{"nctId":"NCT00571506","phase":"PHASE4","title":"Effect of Thiazolidinedione Treatment Vascular Risk Markers","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2004-05","conditions":"Diabetes Mellitus, Type 2, Vascular Diseases","enrollment":25},{"nctId":"NCT00015626","phase":"PHASE2","title":"A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"","conditions":"Insulin Resistance, Diabetes Mellitus","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pioglitazone, Rosiglitazone","genericName":"Pioglitazone, Rosiglitazone","companyName":"Korea University Anam Hospital","companyId":"korea-university-anam-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pioglitazone and rosiglitazone are thiazolidinediones that activate peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}